{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:52:52Z","timestamp":1793440372370,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.eururo.2019.11.021","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T08:53:17Z","timestamp":1576227197000},"page":"494-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"title":["Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study"],"prefix":"10.1016","volume":"77","author":[{"given":"Nobuaki","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Rodriguez-Antolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Feyerabend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris Y.","family":"Alekseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giri","family":"Sulur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Protheroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel","family":"Mundle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"De Porre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namphuong","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2019.11.021_bib0005","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.prnil.2016.07.001","article-title":"Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide","volume":"4","author":"Hassanipour-Azgomi","year":"2016","journal-title":"Prostate Int"},{"key":"10.1016\/j.eururo.2019.11.021_bib0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/pcan.2016.30","article-title":"Increasing incidence of metastatic prostate cancer in the United States (2004\u20132013)","volume":"19","author":"Weiner","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2019.11.021_bib0015","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1200\/JCO.2008.21.5228","article-title":"Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy","volume":"27","author":"Cooperberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrurol.2014.42","article-title":"Prostate cancer in Asian men","volume":"11","author":"Ito","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0025","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \"docetaxel era\": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.11.021_bib0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0040","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0045","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djj129","article-title":"Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16","volume":"98","author":"Petrylak","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2019.11.021_bib0050","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0055","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2019.11.021_bib0060","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0065","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.urology.2011.11.043","article-title":"Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors","volume":"79","author":"Caffo","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.11.021_bib0070","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1464-410X.2012.10959.x","article-title":"Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer","volume":"110","author":"Kijima","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.11.021_bib0075","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1989::AID-CNCR15>3.0.CO;2-V","article-title":"The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate","volume":"83","author":"Vollmer","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.11.021_bib0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/91.3.244","article-title":"Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer","volume":"91","author":"Scher","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2019.11.021_bib0085","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bju.12061","article-title":"The utility of prostate-specific antigen in the management of advanced prostate cancer","volume":"112","author":"Crawford","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.11.021_bib0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2490-14-33","article-title":"Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer","volume":"14","author":"Tomioka","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0095","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/cncr.24064","article-title":"Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy","volume":"115","author":"Choueiri","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.11.021_bib0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.urology.2018.11.056","article-title":"Time to prostate-specific antigen nadir and the risk of death from prostate cancer following radiation and androgen deprivation therapy","volume":"126","author":"Pike","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.11.021_bib0105","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.11.021_bib0115","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-14-1549","article-title":"Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients","volume":"21","author":"Xu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2019.11.021_bib0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.11.021_bib0125","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"10.1016\/j.eururo.2019.11.021_bib0130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2019.37.7_suppl.141","article-title":"Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-na\u00efve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT)","volume":"37","author":"Fizazi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0135","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clinical Oncol"},{"key":"10.1016\/j.eururo.2019.11.021_bib0140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2016.00123","article-title":"Very early PSA response to abiraterone in mCRPC patients: a novel prognostic factor predicting overall survival","volume":"7","author":"Facchini","year":"2016","journal-title":"Front Pharmacol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819308942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819308942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:06:43Z","timestamp":1759583203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283819308942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0302283819308942"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2019.11.021","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2019.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}